# Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

> **NCT00046683** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 284 (—)

## Conditions studied

- B Cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** alemtuzumab

## Key facts

- **NCT ID:** NCT00046683
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 284 (—)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046683, "Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00046683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*